Quoin Pharma reports Q3 net loss of $3.9M, raises up to $105.3M in private placement

Quoin Pharmaceuticals, Ltd.

Net loss of $3.9M for Q3 2025 ($11.5M YTD) vs $2.3M and $6.7M in prior-year periods; R&D spend increased to $2.3M for Q3.
Cash, equivalents, and marketable securities totaled $5.4M as of Sept 30; Oct 2025 added $16.6M upfront from private placement, extending runway into 2027.
Private placement financing closed Oct 2025 with potential gross proceeds up to $105.3M including warrants exercise.
Sally Lawlor appointed CFO; FDA granted Orphan Drug Designation for QRX003 for Netherton Syndrome; pivotal studies to start Q4 2025.
NETHERTON NOW campaign surpassed 1.5M video views since Feb 2025; positive Peeling Skin Syndrome data released.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.